Cowen & Co. Sticks to Their Buy Rating for Neurocrine (NBIX)
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Neurocrine (NBIX) yesterday and set a price target of $115. The company’s shares closed yesterday at $86.97.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 6.0% and a 46.8% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Rocket Pharmaceuticals Inc.
Currently, the analyst consensus on Neurocrine is a Strong Buy with an average price target of $131.90, which is a 51.7% upside from current levels. In a report issued on December 5, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $150 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $126.98 and a one-year low of $68.22. Currently, Neurocrine has an average volume of 854.5K.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NBIX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders.